Changeflow GovPing Pharma & Drug Safety Quinoline cGAS Antagonist Solid Forms and Salts
Routine Notice Added Draft

Quinoline cGAS Antagonist Solid Forms and Salts

Favicon for changeflow.com ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260092048A1 for solid forms and salts of a quinoline cGAS antagonist compound, filed by inventors Jian Qiu, Qi Wei, Heping Shi, Lijun Sun, and Zhijian Chen (Application No. 19316546, filed September 2, 2025). The application discloses the compound's cGAS antagonist properties, methods of preparation, pharmaceutical compositions, and use in medical therapy.

What changed

The patent application discloses novel solid forms and salts of a quinoline compound functioning as a cGAS (cyclic GMP-AMP synthase) antagonist, classified under CPC C07D 401/14. The application covers the chemical compounds, methods for their preparation, pharmaceutical compositions containing them, and their therapeutic applications.

Pharmaceutical companies and drug developers working on cGAS pathway inhibitors should review this filing for potential prior art concerns in related development programs. Patent applications become publicly available 18 months after their earliest priority date; this publication provides insight into the competitive landscape for cGAS-targeted therapeutics.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

SOLID FORMS AND SALTS OF A QUINOLINE CGAS ANTAGONIST COMPOUND

Application US20260092048A1 Kind: A1 Apr 02, 2026

Inventors

Jian Qiu, Qi Wei, Heping Shi, Lijun Sun, Zhijian Chen

Abstract

The present disclosure provides compounds that are cGAS antagonists, solid forms of the compounds, methods of preparation of the compounds and their solid forms, pharmaceutical compositions comprising the compounds and their solid forms, and their use in medical therapy.

CPC Classifications

C07D 401/14

Filing Date

2025-09-02

Application No.

19316546

View original document →

Named provisions

Solid Forms and Salts Methods of Preparation Pharmaceutical Compositions Medical Use

Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260092048A1
Docket
19316546

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Pharmaceutical Development Drug Formulation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.